HealthQuill Contract Development and Manufacturing
Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, has inked two deals worth $897 million with Pfizer to make the US-based company’s products.
Drugs Health Pharma

Samsung Biologics inks $879 million deal with Pfizer to make drugs

HQ Team July 4, 2023: Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, has inked two deals worth $897 million.

Read More